Gastrointestinal stromal tumor. Diagnostic advantages of radiology and endoscopic methods
Abstract
Determination of the advantages (sensitivity, specificity) combining radiology imaging modalities and endoscopy studies in detection of gastrointestinal stromal tumor.
About the Authors
N. T. Tsymzhitova
FGBU N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
B. I. Dolgushin
FGBU N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
I. S. Stilidi
FGBU N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
B. M. Medvedeva
FGBU N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
D. A. Filonenko
FGBU N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
References
1. De Matteo R.P., Heinrich M.C., EL-Rifai W.M. Clinicai management of gastrointestinal stromal tumors: before and after STI- 57. Hum. Patho.1999, v. 30, p. 1213-1220.
2. Fletcher C.D., Berman J.J., Corless C. et al. Diagnosis of gastrointestinal stromal tumors: а consensus approach. Hum. Patol. 2002, v. 33, p. 459-465.
3. Miettinem M., Lasota J. Gastrointestinal stromal tumors definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001, v. 438, p. 1-12.
4. Miettinen M., Lasotа J. Gastrointestinal Stromal Tumors (review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch. Pathol. Lab. Med. 2006, p. 130.
5. Lasota J., Jasinski M., Sarlomo-Rikala M. l. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am. J. Pathol. 1999, v. 154, p. 53-60.
6. Gupta M., Sheppard B.C., Corless C.L. Outcome following surgical therapy for gastrointestinal stromal tumors. J. Gastrointest. Surg. 2006, p. 1099-1105.
7. Demetri G.D., von Mehren M., Blanke C.D.N. Efficacy and safety of imatinibmesylate in advanced gastrointestinal stromal tumors. Engl. J. Med. 2002, v. 347, p. 472-480.
8. Eisenberg B.L., Harris J., Blanke C.D. et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumour (GIST): Early results of RTOG 0132/ACRIN 6665. J. Surg. Oncol. 2009, v. 99, p. 42-47.
9. Ando N., Goto H., Niwa Y. et al. The diagnosis of GI stromal tumors with EUS-guided fine needle aspiration with immunohistochemical analysis. Gastrointest. Endosc. 2002, v. 55, p. 37-43.
10. Connolly E.M., Gaffney E., Reynolds J.V. Gastrointestinal stromal tumors. Br. J. Surg. 2003, v. 90, p. 1178-1186.
Review
For citations:
Tsymzhitova N.T., Dolgushin B.I., Stilidi I.S., Medvedeva B.M., Filonenko D.A. Gastrointestinal stromal tumor. Diagnostic advantages of radiology and endoscopic methods. Bone and soft tissue sarcomas, tumors of the skin. 2014;(1):53-55. (In Russ.)
Views:
62
Email this article 
